| |
Tuesday, October 1, 2024 | 11am ET / 8am PT The clinical trial landscape continues to evolve at a rapid pace. In this webinar, learn how new biomarker detection technologies drive key breakthroughs. With early detection, biomarker testing research can advance disease understanding and management in many care areas. Register now to join us.
|
|
Today’s Big NewsSep 26, 2024 |
| By Darren Incorvaia The NIH has found evidence of research misconduct against Eliezer Masliah, M.D., the head of the National Institute on Aging's (NIA) neuroscience division, the NIH said in a Sept. 26 statement. In addition, Science published an investigation finding that 132 papers published by Masliah contain apparently manipulated images. |
|
|
|
By Angus Liu The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. A group of external advisers to the FDA voted 10-2 that the use of PD-1 inhibitors in first-line, HER2-negative gastric cancer is not favorable in patients who have PD-L1-negative tumors. |
By Conor Hale Immunai has been building a digital map of the immune system by charting each cell type’s function and their interactions with the body and various diseases. |
By Fraiser Kansteiner Arch Venture Partners announced the closing of its 13th venture fund, which is infused with more than $3 billion to support the founding and buildup of early-stage biotech companies. |
|
Tuesday, October 8, 2024 |10am ET / 7am PT In this webinar, you'll learn how companies can navigate the challenges of global expansion after their first regulatory approval. Discover how to make data-driven market entry decisions, launch efficiently, stay adaptable, and leverage commercial partners through case studies and real-life examples. Sign up to join us!
|
|
By Kevin Dunleavy In June at the ASCO conference in Chicago, when AstraZeneca discussed results from a phase 3 trial of its non-small cell lung cancer blockbuster Tagrisso, the presentation received a standing ovation. Three months later, the FDA has added its acclamation, signing off on Tagrisso to become the first targeted therapy for unresectable, stage 3 EGFRm NSCLC. |
By Darren Incorvaia Two biotechs are teaming up to deliver cholesterol-busting mRNA to clogged arteries. Syracuse-based Repair Biotechnologies will use Swiss company Genevant’s lipid nanoparticles to get its cholesterol degrading tech to atherosclerosis plaques, the companies announced on Sept. 26. |
By Nick Paul Taylor Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. self-regulatory body found fault with Novo’s support for U.K pharmacy chains’ weight management services, leading its panel to rule the drugmaker had brought discredit on the pharma industry. |
By Gabrielle Masson Spain-based Asabys Partners has closed a $200 million fund, money that will go toward 12 to 15 companies in biopharma or medtech. |
By Ben Adams As the Centers for Disease Control and Prevention finds that only one-quarter of older adults have received their RSV vaccine, the American Lung Association is launching a new campaign aimed at increasing those rates. |
By Darren Incorvaia On the same day that some Parkinson’s disease drugs are being called into question, AbbVie has announced that its candidate has significantly reduced the burden of the disease in patients compared to placebo, the company announced. |
By Zoey Becker In a phase 3 study called REGENCY, a statistically higher proportion of lupus nephritis patients treated with biannual intravenous Gazyva doses and standard autoimmune disease therapy achieved complete renal responses at 76 weeks compared to those treated with standard therapy alone, Genentech reported Thursday. |
By Conor Hale During the annual meeting of the North American Spine Society, Medtronic said its AiBLE surgical suite would connect with Siemens Healthineers' Multitom Rax robotic X-ray scanner. |
Fierce podcastsDon’t miss an episode |
| | In this week's "Podnosis," Fierce Healthcare’s Anastassia Gliadkovskaya talks to BrightEdge’s Alice Pomponio about investing in cancer-fighting startups and measuring impact. |
|
|---|
|
|
|
The effect of small strands of siRNAs on gene expression has had a
tremendous impact on basic and applied pharmaceutical research.
Download the QPS white paper to learn about siRNA identification,
profiling, and quantitation from the technical experts at QPS.
|
|
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| WhitepaperUnique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
| WhitepaperWhen the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
| WhitepaperPower non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
| WhitepaperFacing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
| WhitepaperWe interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
